Skip to main content

EL PAPEL DE ADAMTS2 EN ESQUIZOFRENIA: NUEVOS CONOCIMIENTOS SOBRE MECANISMOS CEREBRALES IMPLICADOS Y PERSPECTIVAS TERAPEUTICAS BASADO EN MODELOS CELULARES Y ANIMALES.

PID2019-109405RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Shared molecular signature in Alzheimer's disease and schizophrenia: A systematic review of the reelin signaling pathway

  • Valderrama-Mantilla, Ana Isabel
  • Martín-Cuevas, Celia
  • Gómez-Garrido, Ana
  • Morente-Montilla, Cristina
  • Crespo-Facorro, Benedicto
  • García-Cerro, Susana
The Reelin signaling pathway, particularly the RELN-APOER2-DAB1 complex, has emerged as a key contributor to the neuropathology of Alzheimer's disease (AD) and Schizophrenia (SZ). Despite being distinct clinical conditions, these disorders exhibit similar patterns of cognitive decline, including early disruptions in synaptic function and memory impairments. Notably, individuals with SZ have a 2-4 fold increased risk of developing AD or other dementias, highlighting potential shared molecular mechanisms, and positioning Reelin as a pivotal link between them. This systematic review explores the role of Reelin and its signaling components across these disorders. In AD, Reelin disruption correlates with hallmark features such as Tau hyperphosphorylation, amyloid-beta accumulation, and cognitive deficits. In SZ, alterations in Reelin signaling, including epigenetic modifications affecting RELN expression, are linked to disruptions in neuronal development and synaptic plasticity, particularly in the parietal and prefrontal cortices. Additionally, genomic studies reveal specific RELN variants and allelic imbalances that may influence disease severity and treatment response in SZ, suggesting RELN's role as a potential biomarker for therapeutic outcomes. Region-specific Reelin alterations in both AD and SZ suggest differing impacts yet underscore a potential common molecular origin. Our findings highlight the Reelin pathway as a molecular convergence point, warranting further investigation as a therapeutic and diagnostic target for AD, SZ, and potentially other neuropsychiatric disorders. The interplay between genetic and epigenetic regulation of RELN may provide novel insights into neurodegeneration, with implications for personalized intervention strategies in AD and SZ., This work was supported by PID2019-109405RB-I00 / AEI / 10.13039/501100011033; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811 and fellowship PREDOC_02201; the Regional Ministry of Health (Junta de Andalucía) through project PI-0014-2022; the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through projects AC23_2/00034 and PI22/01379, the Sara Borrell fellowship (CD19_00183), the M-AES mobility grant (MV22/00107), and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26). AIV-M did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. CM-C and CM-M were supported by the Instituto de Salud Carlos III (AC23_2/00034 and FI23/00221, respectively). AG-G was supported by a predoctoral contract of the Andalusian System of Knowledge (PREDOC_02201). BC-F received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the Seventh European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson and Johnson, Mylan, Lundbeck, and Otsuka Pharmaceuticals. SG-C was supported by a Sara Borrell contract (CD19_00183) provided by the Carlos III Health Institute., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial signals in the bloodstream: Peripheral signature of mitochondrial dysfunction in mental health. A systematic review

  • Fernández-Pech, Inés Lucía
  • Fernández-Guillén, María
  • Morente-Montilla, Cristina
  • Crespo-Facorro, Benedicto
  • Martín-Cuevas, Celia
Psychiatric disorders are characterized by marked clinical heterogeneity, overlapping symptom dimensions, and the persistent lack of objective biomarkers. Liquid biopsy has emerged as a promising, non-invasive strategy to identify peripheral molecular signatures that may inform diagnosis and treatment monitoring. Given the central involvement of mitochondrial dysfunction in psychiatric pathophysiology, circulating cell-free mitochondrial DNA (ccf-mtDNA) has attracted increasing interest as a candidate biomarker. Following PRISMA 2020 guidelines, this systematic review synthesized evidence on ccf-mtDNA alterations in bipolar disorder (BD), depressive disorders (DD), and schizophrenia (SCZ). Findings in BD were heterogeneous: several studies reported elevated ccf-mtDNA, particularly in unmedicated individuals and those with cognitive deficits, whereas others observed no differences or even decreased levels compared with healthy controls (HC). In DD, evidence more consistently indicated increased ccf-mtDNA, especially in unmedicated or late-life depression, where higher levels correlated with symptom severity, frailty, and inflammatory indices. These data support ccf-mtDNA as a peripheral marker of mitochondrial and inflammatory dysregulation in DD. Conversely, most studies in SCZ reported no significant differences relative to HC; however, elevated ccf-mtDNA levels observed in cognitively impaired subgroups and in patients exhibiting alterations in brain bioenergetics point to underlying clinical and biological heterogeneity. Collectively, current evidence implicates ccf-mtDNA as a putative biomarker of mitochondrial dysfunction in psychiatry, with greater translational potential in DD and BD. Nonetheless, methodological heterogeneity, small sample sizes, and cross-sectional designs underscore the need for standardized, longitudinal investigations to establish its diagnostic and prognostic validity., This work was supported by the Consejería de Conocimiento y Universidades through project PID2019–109405RB-I00 / AEI / 10.13039/501100011033; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811; the Regional Ministry of Health (Junta de Andalucía) through project PI-0014–2022; the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through projects AC23_2/00034 and PI22/01379, and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26). ILF-P did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. MF-G was supported by the Spanish Network for Research in Mental Health (CIBERSAM). CM-M was supported by a predoctoral contract of the Instituto de Salud Carlos III (FI23/00221). BC-F received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the Seventh European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson and Johnson, Mylan, Lundbeck, and Otsuka Pharmaceuticals. CM-C was supported by the Instituto de Salud Carlos III (AC23_2/00034)., Peer reviewed